NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.27-8.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · NRXP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
This attestation has been provided to the FDA and the Company aims for 2026 approval and commercialization.
Stated in 1 of 1 supplied quarters. Management reported: “This attestation has been provided to the FDA and the Company aims for 2026 approval and commercialization.” “Accordingly, five million units of launch stock is currently in the manufacturing process with anticipated post launch manufacture of 1 million units per month.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“This attestation has been provided to the FDA and the Company aims for 2026 approval and commercialization.”
With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval.
Stated in 1 of 1 supplied quarters. Management reported: “NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression.” “With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval.”
“With alignment on the drug packaging matter, the Company is now poised to finalize its NDA, aiming for 2027 approval.”
[/TABLE] [TABLE] ● | Closed an institutionally-supported, underwritten public offering of common stock for gross proceeds of $22.3 million, including full exercise of the underwriters’ option.
Stated in 1 of 1 supplied quarters. Management reported: “As of June 30, 2026, the Company had approximately $26.7 million in cash and cash equivalents versus $7.8 million as of December 31, 2025.” “Management believes current cash resources, anticipated growth in clinic revenue, and opportunistic utilization of the Company's active at-the-market offering facility will be sufficient to support operations for at least one year.”
“[/TABLE] [TABLE] ● | Closed an institutionally-supported, underwritten public offering of common stock for gross proceeds of $22.3 million, including full exercise of the underwriters’ option.”
Establish commercial team and manufacturing capacity to support product launch and market entry.
Focus on reducing operating losses and improving operating income over time.
Over the trailing year it converted 0.48x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.